- Home
- GOSS vs BOE Comparison
GOSS vs BOE Comparison
Compare GOSS & BOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOSS | BOE |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.2M | 643.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | GOSS | BOE |
|---|---|---|
| Price | $2.89 | $11.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $8.60 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 166.1K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.30% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,051,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.76 | $8.80 |
| 52 Week High | $3.87 | $10.48 |
Technical Indicators
Market Signals| Indicator | GOSS | BOE |
|---|---|---|
| Relative Strength Index (RSI) | 39.59 | 58.23 |
| Support Level | $3.04 | $11.71 |
| Resistance Level | $3.87 | $11.77 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 1.49 | 75.02 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest
Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.